Solid organ transplantation from hepatitis B virus-positive donors

Consensus guidelines for recipient management

S. Huprikar, L. Danziger-Isakov, J. Ahn, S. Naugler, E. Blumberg, Robin Avery, C. Koval, E. D. Lease, A. Pillai, K. E. Doucette, J. Levitsky, M. I. Morris, K. Lu, J. K. McDermott, T. Mone, J. P. Orlowski, D. M. Dadhania, K. Abbott, S. Horslen, B. L. Laskin & 9 others A. Mougdil, V. L. Venkat, K. Korenblat, V. Kumar, P. Grossi, R. D. Bloom, K. Brown, C. N. Kotton, D. Kumar

Research output: Contribution to journalArticle

Abstract

Use of organs from donors testing positive for hepatitis B virus (HBV) may safely expand the donor pool. The American Society of Transplantation convened a multidisciplinary expert panel that reviewed the existing literature and developed consensus recommendations for recipient management following the use of organs from HBV positive donors. Transmission risk is highest with liver donors and significantly lower with non-liver (kidney and thoracic) donors. Antiviral prophylaxis significantly reduces the rate of transmission to liver recipients from isolated HBV core antibody positive (anti-HBc+) donors. Organs from anti-HBc+ donors should be considered for all adult transplant candidates after an individualized assessment of the risks and benefits and appropriate patient consent. Indefinite antiviral prophylaxis is recommended in liver recipients with no immunity or vaccine immunity but not in liver recipients with natural immunity. Antiviral prophylaxis may be considered for up to 1 year in susceptible non-liver recipients but is not recommended in immune non-liver recipients. Although no longer the treatment of choice in patients with chronic HBV, lamivudine remains the most cost-effective choice for prophylaxis in this setting. Hepatitis B immunoglobulin is not recommended.

Original languageEnglish (US)
Pages (from-to)1162-1172
Number of pages11
JournalAmerican Journal of Transplantation
Volume15
Issue number5
DOIs
StatePublished - May 1 2015

Fingerprint

Organ Transplantation
Hepatitis B virus
Tissue Donors
Guidelines
Antiviral Agents
Liver
Immunity
Hepatitis B Antibodies
Lamivudine
Chronic Hepatitis B
Hepatitis B
Innate Immunity
Immunoglobulins
Thorax
Vaccines
Transplants
Kidney
Costs and Cost Analysis

Keywords

  • clinical research/practice
  • donors and donation: donor-derived infections
  • infection and infectious agents
  • infectious disease
  • viral: hepatitis B

ASJC Scopus subject areas

  • Transplantation
  • Immunology and Allergy
  • Pharmacology (medical)
  • Medicine(all)

Cite this

Solid organ transplantation from hepatitis B virus-positive donors : Consensus guidelines for recipient management. / Huprikar, S.; Danziger-Isakov, L.; Ahn, J.; Naugler, S.; Blumberg, E.; Avery, Robin; Koval, C.; Lease, E. D.; Pillai, A.; Doucette, K. E.; Levitsky, J.; Morris, M. I.; Lu, K.; McDermott, J. K.; Mone, T.; Orlowski, J. P.; Dadhania, D. M.; Abbott, K.; Horslen, S.; Laskin, B. L.; Mougdil, A.; Venkat, V. L.; Korenblat, K.; Kumar, V.; Grossi, P.; Bloom, R. D.; Brown, K.; Kotton, C. N.; Kumar, D.

In: American Journal of Transplantation, Vol. 15, No. 5, 01.05.2015, p. 1162-1172.

Research output: Contribution to journalArticle

Huprikar, S, Danziger-Isakov, L, Ahn, J, Naugler, S, Blumberg, E, Avery, R, Koval, C, Lease, ED, Pillai, A, Doucette, KE, Levitsky, J, Morris, MI, Lu, K, McDermott, JK, Mone, T, Orlowski, JP, Dadhania, DM, Abbott, K, Horslen, S, Laskin, BL, Mougdil, A, Venkat, VL, Korenblat, K, Kumar, V, Grossi, P, Bloom, RD, Brown, K, Kotton, CN & Kumar, D 2015, 'Solid organ transplantation from hepatitis B virus-positive donors: Consensus guidelines for recipient management', American Journal of Transplantation, vol. 15, no. 5, pp. 1162-1172. https://doi.org/10.1111/ajt.13187
Huprikar, S. ; Danziger-Isakov, L. ; Ahn, J. ; Naugler, S. ; Blumberg, E. ; Avery, Robin ; Koval, C. ; Lease, E. D. ; Pillai, A. ; Doucette, K. E. ; Levitsky, J. ; Morris, M. I. ; Lu, K. ; McDermott, J. K. ; Mone, T. ; Orlowski, J. P. ; Dadhania, D. M. ; Abbott, K. ; Horslen, S. ; Laskin, B. L. ; Mougdil, A. ; Venkat, V. L. ; Korenblat, K. ; Kumar, V. ; Grossi, P. ; Bloom, R. D. ; Brown, K. ; Kotton, C. N. ; Kumar, D. / Solid organ transplantation from hepatitis B virus-positive donors : Consensus guidelines for recipient management. In: American Journal of Transplantation. 2015 ; Vol. 15, No. 5. pp. 1162-1172.
@article{bdfa8fbb3a7b4689aeb80bb9bd9ae2d5,
title = "Solid organ transplantation from hepatitis B virus-positive donors: Consensus guidelines for recipient management",
abstract = "Use of organs from donors testing positive for hepatitis B virus (HBV) may safely expand the donor pool. The American Society of Transplantation convened a multidisciplinary expert panel that reviewed the existing literature and developed consensus recommendations for recipient management following the use of organs from HBV positive donors. Transmission risk is highest with liver donors and significantly lower with non-liver (kidney and thoracic) donors. Antiviral prophylaxis significantly reduces the rate of transmission to liver recipients from isolated HBV core antibody positive (anti-HBc+) donors. Organs from anti-HBc+ donors should be considered for all adult transplant candidates after an individualized assessment of the risks and benefits and appropriate patient consent. Indefinite antiviral prophylaxis is recommended in liver recipients with no immunity or vaccine immunity but not in liver recipients with natural immunity. Antiviral prophylaxis may be considered for up to 1 year in susceptible non-liver recipients but is not recommended in immune non-liver recipients. Although no longer the treatment of choice in patients with chronic HBV, lamivudine remains the most cost-effective choice for prophylaxis in this setting. Hepatitis B immunoglobulin is not recommended.",
keywords = "clinical research/practice, donors and donation: donor-derived infections, infection and infectious agents, infectious disease, viral: hepatitis B",
author = "S. Huprikar and L. Danziger-Isakov and J. Ahn and S. Naugler and E. Blumberg and Robin Avery and C. Koval and Lease, {E. D.} and A. Pillai and Doucette, {K. E.} and J. Levitsky and Morris, {M. I.} and K. Lu and McDermott, {J. K.} and T. Mone and Orlowski, {J. P.} and Dadhania, {D. M.} and K. Abbott and S. Horslen and Laskin, {B. L.} and A. Mougdil and Venkat, {V. L.} and K. Korenblat and V. Kumar and P. Grossi and Bloom, {R. D.} and K. Brown and Kotton, {C. N.} and D. Kumar",
year = "2015",
month = "5",
day = "1",
doi = "10.1111/ajt.13187",
language = "English (US)",
volume = "15",
pages = "1162--1172",
journal = "American Journal of Transplantation",
issn = "1600-6135",
publisher = "Wiley-Blackwell",
number = "5",

}

TY - JOUR

T1 - Solid organ transplantation from hepatitis B virus-positive donors

T2 - Consensus guidelines for recipient management

AU - Huprikar, S.

AU - Danziger-Isakov, L.

AU - Ahn, J.

AU - Naugler, S.

AU - Blumberg, E.

AU - Avery, Robin

AU - Koval, C.

AU - Lease, E. D.

AU - Pillai, A.

AU - Doucette, K. E.

AU - Levitsky, J.

AU - Morris, M. I.

AU - Lu, K.

AU - McDermott, J. K.

AU - Mone, T.

AU - Orlowski, J. P.

AU - Dadhania, D. M.

AU - Abbott, K.

AU - Horslen, S.

AU - Laskin, B. L.

AU - Mougdil, A.

AU - Venkat, V. L.

AU - Korenblat, K.

AU - Kumar, V.

AU - Grossi, P.

AU - Bloom, R. D.

AU - Brown, K.

AU - Kotton, C. N.

AU - Kumar, D.

PY - 2015/5/1

Y1 - 2015/5/1

N2 - Use of organs from donors testing positive for hepatitis B virus (HBV) may safely expand the donor pool. The American Society of Transplantation convened a multidisciplinary expert panel that reviewed the existing literature and developed consensus recommendations for recipient management following the use of organs from HBV positive donors. Transmission risk is highest with liver donors and significantly lower with non-liver (kidney and thoracic) donors. Antiviral prophylaxis significantly reduces the rate of transmission to liver recipients from isolated HBV core antibody positive (anti-HBc+) donors. Organs from anti-HBc+ donors should be considered for all adult transplant candidates after an individualized assessment of the risks and benefits and appropriate patient consent. Indefinite antiviral prophylaxis is recommended in liver recipients with no immunity or vaccine immunity but not in liver recipients with natural immunity. Antiviral prophylaxis may be considered for up to 1 year in susceptible non-liver recipients but is not recommended in immune non-liver recipients. Although no longer the treatment of choice in patients with chronic HBV, lamivudine remains the most cost-effective choice for prophylaxis in this setting. Hepatitis B immunoglobulin is not recommended.

AB - Use of organs from donors testing positive for hepatitis B virus (HBV) may safely expand the donor pool. The American Society of Transplantation convened a multidisciplinary expert panel that reviewed the existing literature and developed consensus recommendations for recipient management following the use of organs from HBV positive donors. Transmission risk is highest with liver donors and significantly lower with non-liver (kidney and thoracic) donors. Antiviral prophylaxis significantly reduces the rate of transmission to liver recipients from isolated HBV core antibody positive (anti-HBc+) donors. Organs from anti-HBc+ donors should be considered for all adult transplant candidates after an individualized assessment of the risks and benefits and appropriate patient consent. Indefinite antiviral prophylaxis is recommended in liver recipients with no immunity or vaccine immunity but not in liver recipients with natural immunity. Antiviral prophylaxis may be considered for up to 1 year in susceptible non-liver recipients but is not recommended in immune non-liver recipients. Although no longer the treatment of choice in patients with chronic HBV, lamivudine remains the most cost-effective choice for prophylaxis in this setting. Hepatitis B immunoglobulin is not recommended.

KW - clinical research/practice

KW - donors and donation: donor-derived infections

KW - infection and infectious agents

KW - infectious disease

KW - viral: hepatitis B

UR - http://www.scopus.com/inward/record.url?scp=84928058599&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84928058599&partnerID=8YFLogxK

U2 - 10.1111/ajt.13187

DO - 10.1111/ajt.13187

M3 - Article

VL - 15

SP - 1162

EP - 1172

JO - American Journal of Transplantation

JF - American Journal of Transplantation

SN - 1600-6135

IS - 5

ER -